Replimune’s RP1+nivolumab melanoma BLA faces an FDA decision by Apr 10, 2026. The current cash runway extends to Q1'27. See more on REPL stock here.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Celtic symbols can be beautifully intricate and, in some cases, filled with intense mystery as to the various meanings behind them. The symbols held incredibly meaningful powers in the lives of those ...

Hurricane Milton is barreling toward Florida, where it is projected to make landfall Wednesday night. The storm has been downgraded to a Category 4 hurricane, but the National Hurricane Center (NHC) ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...